Edwards Lifesciences Corporation EW announced its decision to acquire Innovalve Bio Medical Ltd., an early-stage transcatheter mitral valve replacement (TMVR) company. This follows Edwards Lifescience ...

The transcatheter mitral valve replacement (TMVR) market is projected to grow at a CAGR of 20% over the forecast period. Major factors driving growth include increased prevalence of mitral valve ...

US-based medical device giant Edwards Lifesciences has announced that it is exercising its option to completely acquire Israeli company Innovalve Bio Medical to advance its early-stage transcatheter ...

Edwards Lifesciences EW announced that the FDA approved its SAPIEN M3 transcatheter mitral valve replacement system, making it the first minimally invasive, catheter-based treatment that uses a ...

Edwards Lifesciences Corp. (NYSE: EW) today announced its plans to acquire Innovalve Bio Medical, an early stage transcatheter mitral valve replacement (TMVR) company, for about $300 million in cash.

Edwards Lifesciences announced Thursday that the California company has completed three first-in-human implants of the company’s transcatheter mitral valve replacement system. But it is not the only ...

After years of interest in and anticipation about the potential for transcatheter mitral valve replacement (TMVR), Edwards Lifesciences is ready to kick off a CE Mark trial for its TMVR system. The ...

Edwards Lifesciences (EW) announced on Tuesday that the U.S. Food and Drug Administration approved its SAPIEN M3 transcatheter mitral valve replacement (TMVR) system for patients with mitral ...

Intentionally tearing the anterior mitral valve leaflet may prevent one of the most serious and life-threatening complications of transcatheter mitral valve replacement (TMVR)—left ventricular outflow ...

Premium heart valve manufacturer Edwards Lifesciences Corp.EW recently completed the acquisition of California-based CardiAQ Valve Technologies, Inc. - a privately held medical device developer of ...

For patients with significant mitral regurgitation (MR) who are unsuitable for surgical intervention or transcatheter edge-to-edge repair (TEER), transcatheter mitral valve replacement (TMVR) appears ...